ADMA BIOLOGICS, INC. Proceeds from Lines of Credit
ADMA BIOLOGICS, INC. (ADMA) reported Proceeds from Lines of Credit of $30.00 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2025-08-06
- 2025-06-30: Proceeds from Lines of Credit 6 month $30.00M.
- 2024-06-30: Proceeds from Lines of Credit 6 month $0.00.
| Period end | Proceeds from Lines of Credit 6 month |
|---|---|
| 2025-06-30 | $30.00M 10-Q · filed 2025-08-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |